BiomX Inc (PHGE) Stock Analysis
Verdict: AVOID
Terminal liquidity risk and a massive 1950% earnings miss outweigh speculative technical momentum in a pre-revenue microcap biotech.
Investment score: 22/100
Analysis as of
Is BiomX Inc stock worth reviewing? The TradeMates thesis
BiomX is in a fundamental crisis with zero revenue, a massive earnings miss, and a balance sheet that suggests imminent dilution or insolvency.
7-factor investment score
- Valuation: 5/100 (weight 20%)
- Financial Health: 10/100 (weight 15%)
- Technical Momentum: 45/100 (weight 15%)
- Earnings Quality: 5/100 (weight 15%)
- Insider Sentiment: 10/100 (weight 10%)
- Analyst Consensus: 30/100 (weight 10%)
- Risk-Adjusted Return: 20/100 (weight 15%)
BiomX Inc opportunities and risks
What speaks for PHGE
- Phage Therapy Pipeline Progress
What speaks against PHGE
- Imminent Insolvency / Massive Dilution
Peers and competitors
- CELZ
- PMCB
- GNPX
- ACXP
- NKGN
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| PHGE | n/a | 0.0x | n/a | 0.0% | 0.0% | -923.1% |
| CELZ | n/a | 1995.7x | n/a | -3986.6% | -192066.3% | -93.3% |
| PMCB | n/a | 0.0x | 1.2x | 0.0% | 0.0% | -90.2% |
| GNPX | n/a | 0.0x | 1.0x | 0.0% | 0.0% | -1094.5% |
| ACXP | n/a | 0.0x | 0.8x | 0.0% | 0.0% | -190.0% |
| NKGN | n/a | 12.0x | 47.3x | 50.0% | -2157.1% | -124.9% |
| Peer median | n/a | 0.0x | 1.0x | 0.0% | 0.0% | -124.9% |
Frequently asked questions about BiomX Inc (PHGE)
Is PHGE stock a good investment?
The TradeMates model rates BiomX Inc as AVOID with an investment score of 22/100. BiomX is in a fundamental crisis with zero revenue, a massive earnings miss, and a balance sheet that suggests imminent dilution or insolvency. This is algorithmic model output, not personal investment advice.
Is PHGE stock a buy?
The TradeMates model verdict for PHGE is AVOID with an investment score of 22/100. Treat this as a model signal to review, not a personal buy recommendation.